Active substance    Tafasitamab
Holder Clinigen Healthcare Ltd on behalf of Incyte Ltd
Status closed
Indication the treatment of adult patients who have Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and who are not eligible for autologous stem cell transplantation (ASCT)
Public documents Approbation
  Information for the patient
  Informed consent
Last update 26/10/2023


Last updated on 23/04/2024